Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer.
作者信息
Kirman Irena
机构信息
Columbia University, 630 W 168 Street, New York City, New York, USA.
出版信息
Curr Opin Mol Ther. 2006 Aug;8(4):358-65.
PMID:16955700
Abstract
Igeneon GmbH, a wholly owned subsidiary of Aphton Corp, is developing IGN-101, an anticancer vaccine containing the EpCAM-targeting aluminum-adsorbed munrine monoclonal antibody 17-1A (edrecolomab), for the potential subcutaneous treatment of epithelial cancers such as colorectal and rectal tumors. By February 2004, Igeneon was seeking to outlicense the drug.
摘要
Zotero 插件